Grasscity - Dab Rig Sale - 50% Discount
Food and Drug Administration (FDA) Disclosure:

The statements in this forum have not been evaluated by the Food and Drug Administration and are generated by non-professional writers. Any products described are not intended to diagnose, treat, cure, or prevent any disease.

Website Disclosure:

This forum contains general information about diet, health and nutrition. The information is not advice and is not a substitute for advice from a healthcare professional.

Mouse study- CBDV vs Fragile X Syndrome

Discussion in 'Medical Marijuana Usage and Applications' started by Storm Crow, Aug 14, 2023.

  1. Fragile X syndrome is a genetic disorder that affects humans and causes mental and behavioral delays, seizures, hyperactivity, and is marked by a narrow face, large head, large ears, flexible joints, and a prominent forehead. It is about twice as common in boys than girls.

    Now there is a mutated mice with a genetic flaw that is very much like Fragile X. When adolescent mice of this strain were given CBDV, the young mice developed in a much more normal manner!

    I've done a plain language translation for the abstract in italics- just in case you just had a puff!. :GettingStoned:



    Early Administration of the Phytocannabinoid Cannabidivarin Prevents the Neurobehavioral Abnormalities Associated with the Fmr1-KO Mouse Model of Fragile X Syndrome. (France/ Italy/ USA/ UK) (full – 2023) Early Administration of the Phytocannabinoid Cannabidivarin Prevents the Neurobehavioral Abnormalities Associated with the Fmr1-KO Mouse Model of Fragile X Syndrome

    Phytocannabinoids, including the non-addictive cannabis component cannabidivarin (CBDV), have been reported to hold therapeutic potential in several neurodevelopmental disorders (NDDs). Nonetheless, the therapeutic value of phytocannabinoids for treating Fragile X syndrome (FXS), a major NDD, remains unexplored.

    CBDV has been reported to help some neurodevelopmental disorders, so the scientists looked at CBDV.

    Here, we characterized the neurobehavioral effects of CBDV at doses of 20 or 100 mg/kg in the Fmr1-knockout (Fmr1-KO) mouse model of FXS using two temporally different intraperitoneal regimens: subchronic 10-day delivery during adulthood (Study 1: rescue treatment) or chronic 5-week delivery at adolescence (Study 2: preventive treatment).

    The scientists looked at using CBDV in either adult or adolescent "FXS" mutant mice by giving them shots of CBDV.

    Behavioral tests assessing FXS-like abnormalities included anxiety, locomotor, cognitive, social and sensory alterations. Expression of inflammatory and plasticity markers was investigated in the hippocampus and prefrontal cortex.

    They tested the behavior of the mice in various ways and also looked at the hippocampus part of the brains of the mice for inflammation and more.

    When administered during adulthood (Study 1), the effects of CBDV were marginal, rescuing at the lower dose only the acoustic hyper-responsiveness of Fmr1-KO mice and at both doses their altered hippocampal expression of neurotrophins.

    In the adult FXS mice, the effects were minimal, but the mice did stop freaking out to noises (an exaggerated acoustic startle response, which is "normal" for the FXS mice,) and made their brain chemistry a bit closer to normal.

    When administered during adolescence (Study 2), CBDV at both doses prevented the cognitive, social and acoustic alterations of adult Fmr1-KO mice and modified the expression of several inflammatory brain markers in both wild-type littermates and mutants.

    In adolescent mice, the results were much more promising! All of the Fragile X-like traits were wiped out, except the hyperactivity. The littermates of the mutant mice often have somewhat abnormally high brain inflammation and the CBDV reduced it in them.

    These findings warrant the therapeutic potential of CBDV for preventing neurobehavioral alterations associated with FXS, highlighting the relevance of its early administration.

    Since CBDV prevented the changes found in FXS in adolescent mice, but only had some effect on older mice, further study is needed!



    Now the difference in the effects between adolescent and adult mice is very interesting. I (and likely the scientists) think the next study should be done with new-born and very young mice of various ages to see if, in spite of their genetic defect, they grow up normally!

    This may be a major break-through in Fragile X, but the fact is, what works in mice, does not always work in humans. Yet, it does pan out, this could be a major change for the treatment of Fragile X!

    And this goes to show us another possible, and rather unexpected, benefit from the natural cannabinoids beyond THC and CBD!

    Granny :wave:

     
    • Like Like x 1

Share This Page